pharmastrategyblog.com
Pharma Strategy Blog | Commentary on Pharma & Biotech Oncology / Hematology New Product DevelopmentCommentary on Pharma & Biotech Oncology / Hematology New Product Development
http://www.pharmastrategyblog.com/
Commentary on Pharma & Biotech Oncology / Hematology New Product Development
http://www.pharmastrategyblog.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Tuesday
LOAD TIME
1.5 seconds
16x16
Contact Privacy Inc. Customer 0129962973
Contact Privacy Inc. Customer 0129962973
96 M●●●● Ave
To●●to , ON, M6K 3M1
CA
View this contact
Contact Privacy Inc. Customer 0129962973
Contact Privacy Inc. Customer 0129962973
96 M●●●● Ave
To●●to , ON, M6K 3M1
CA
View this contact
Contact Privacy Inc. Customer 0129962973
Contact Privacy Inc. Customer 0129962973
96 M●●●● Ave
To●●to , ON, M6K 3M1
CA
View this contact
BUY YOUR DOMAIN
15
YEARS
7
MONTHS
12
DAYS
TUCOWS DOMAINS INC.
WHOIS : whois.tucows.com
REFERRED : http://domainhelp.opensrs.net
PAGES IN
THIS WEBSITE
13
SSL
EXTERNAL LINKS
225
SITE IP
104.197.56.171
LOAD TIME
1.469 sec
SCORE
6.2
Pharma Strategy Blog | Commentary on Pharma & Biotech Oncology / Hematology New Product Development | pharmastrategyblog.com Reviews
https://pharmastrategyblog.com
Commentary on Pharma & Biotech Oncology / Hematology New Product Development
pharmastrategyblog.com
What's hot at ECCO 2013 in Amsterdam? #ECC2013 | Pharma Strategy Blog
https://pharmastrategyblog.com/2013/09/whats-hot-at-ecco-2013-preview-of-late-breakers-and-pi3k-abstracts.html
Commentary on Pharma and Biotech Oncology / Hematology New Product Development. What’s hot at ECCO 2013 – Preview of late breakers and PI3K abstracts. On September 17, 2013. Next I’ll be off to the European Cancer Congress (ECC) in Amsterdam. This meeting alternates each year between ECCO and ESMO hosting the event at a different European city. If you missed my colleague Pieter Droppert’s ECCO highlights yesterday, you can catch them here. Including details of the iPad app and abstracts. The study looks ...
How KRAS and NRAS mutations affect efficacy of EGFR therapies in colorectal cancer | Pharma Strategy Blog
https://pharmastrategyblog.com/2013/09/update-on-kras-and-nras-mutations-in-colorectal-cancer.html
Commentary on Pharma and Biotech Oncology / Hematology New Product Development. Update on KRAS and NRAS mutations in colorectal cancer. On September 19, 2013. A new NEJM article on KRAS and metastatic colorectal cancer (CRC) caught my eye last week. One of the challenges with this disease is the limited effectiveness of EGFR monoclonal antibodies such as cetuximab (Erbitux) and panitumumab (Vectibix). However, science is very instructive sometimes, as Dr Berlin noted in his NEJM editorial last week:.
Science Fridays | Pharma Strategy Blog
https://pharmastrategyblog.com/science-fridays
Commentary on Pharma and Biotech Oncology / Hematology New Product Development. Update on RAF resistance in metastatic melanoma. The state of play in overcoming resistance to RAF inhibition in metastatic melanoma - where do we go next? January 31, 2014. Developing a predictive biomarker for PARP inhibition. Is CDK12 deficiency a clinically relevant predictive biomarker of PARP1/2 inhibitor sensitivity? February 7, 2014. Removing the PD-1 brake enhances the effect on adoptive CAR T cells. October 16, 2013.
AACR 2013 - overcoming drug resistance in lung cancer | Pharma Strategy Blog
https://pharmastrategyblog.com/2013/04/overcoming-drug-resistance-in-lung-cancer.html
Commentary on Pharma and Biotech Oncology / Hematology New Product Development. Overcoming drug resistance in lung cancer. On the final day of the annual 2013 meeting of the American Association for Cancer Research (AACR) in Washington DC, Jeffrey Engelman (MGH) hosted an excellent plenary session on Cancer Evolution and Resistance with a series of superb talks not only from himself, but also Neal Rosen (MSKCC), Todd Golub (Broad Institute) and René Bernards (Netherlands CI). Thus we can see that the res...
Idelalisib and PI3K-delta in NHL and CLL | Pharma Strategy Blog
https://pharmastrategyblog.com/2014/01/making-a-difference-in-nhl-and-cll-an-interview-with-dr-carol-gallagher.html
Commentary on Pharma and Biotech Oncology / Hematology New Product Development. Making a difference in NHL and CLL: an interview with Dr Carol Gallagher. For as long as anyone can remember, humanity has wondered, “Why do we do things even when we know we should not? James Shelley, Caesura Letters. Or even specific, well defined subsets to improve the homogeneity ratio? Or perhaps they knowingly underpower a randomized trial for overall survival? The list goes on…. A head-desk kind of moment to be sure.
TOTAL PAGES IN THIS WEBSITE
13
SABCS 2013: What I’m most looking forward to seeing this year | thecancergeek
https://thecancergeek.wordpress.com/2013/12/10/sabcs-2013-what-im-most-looking-forward-to-seeing-this-year
It really shouldn’t be up to a patient to know. →. December 10, 2013 · 9:22 am. SABCS 2013: What I’m most looking forward to seeing this year. Well the annual San Antonio Breast Cancer Symposium is here and I’m very excited to be here to learn what’s new and upcoming in the world of research and clinical care. I meant to get this post up before I left, but my lab work this weekend had other ideas. Just a quickie post from the hotel this morning before the sessions start for real this afternoon. I-SPY2 is...
Blizzards and the American Work Ethic | Biojobblog
http://biojobsblog.com/2015/01/27/blizzards-and-the-american-work-ethic
Biotechnology and Biopharmaceutical Jobs BioJob Blogger Clifford Mintz. Skip to primary content. Skip to secondary content. A biocareer development and life science industry information blog authored by Clifford S. Mintz, PhD. Blizzards and the American Work Ethic. January 27, 2015. Put simply, looking for cataclysmic climatic events to get the vacation time that employees so desperately need is not in the best interest of the American workforce! Until next time…. Receive BioJobBlog via e-mail.
Welcome and Disclosures | FeedingBiotech
https://feedingbiotech.com/12-2
Welcome and thanks for stopping by. Discussions around small and microcap biotech companies will likely predominate, but random thoughts are bound to percolate through. If I do own shares of a company, it will be disclosed – make sure you take any comments about them with a grain of salt and be sure to explain to me what I might have missed, so I that can exit! Biotech/Pharmaceutical Insights (Twitter Follow). Http:/ pipeline.corante.com. Http:/ www.gekkowire.com. Http:/ www.trokalayjian.com. Lastly, I w...
cannabis | Biojobblog
http://biojobsblog.com/tag/cannabis
Biotechnology and Biopharmaceutical Jobs BioJob Blogger Clifford Mintz. Skip to primary content. Skip to secondary content. A biocareer development and life science industry information blog authored by Clifford S. Mintz, PhD. Cannabis-Derived Pharmaceuticals: The Next Generation? July 13, 2015. My colleagues AJ Fabrizio and Evan Nison of TerraTech Corp. And I just published an article in the July 2015 issue of the Journal of Commercial Biotechnology entitled “ Cannabis-Derived Pharmaceuticals. Making Ne...
hematologymarketinsights.blogspot.com
Hematology Competitive Insights: Second-line treatment in CML
http://hematologymarketinsights.blogspot.com/2008/07/second-line-treatment-in-cml.html
Tuesday, July 29, 2008. Second-line treatment in CML. MD Anderson Cancer Center recently published a new article in Blood. Looking at second-line treatment with tyrosine kinase therapies with nilotinib. Failure. This is a crucial question - how long should patients receive their new therapy before considering alternative treatments? Thanks for this useful post. Here is some additional information about the genetics of this condition that was written by our Genetic Counselor and other genetic professi...
hematologymarketinsights.blogspot.com
Hematology Competitive Insights: May 2008
http://hematologymarketinsights.blogspot.com/2008_05_01_archive.html
Monday, May 12, 2008. Knocking out cancer cells in Leukemia. Cancer initiating cells (CICs) or leukemia initiating cells (LICs) are stealth populations impervious to conventional chemotherapy and resistant to targeted cancer therapies. When a leukemia patient relapses following a period of remission, it is the LICs that are the cause of the disease’s re-emergence. Researchers at the Beth Israel Deaconess Medical Center. Their findings, which appear in Nature. The concept is a very simple one; 90% of exis...
desafiandomelanoma.blogspot.com
Desafiando o Melanoma: Dias melhores virão?
http://desafiandomelanoma.blogspot.com/2012/03/dias-melhores-virao.html
Never, Never, Never Give Up" (Winston Churchill). Sexta-feira, 16 de março de 2012. Ana Cintia Cassab Heilborn. Compartilhar com o Pinterest. 19 de março de 2012 10:52. Li em outros sites a respeito do aveloz, não sei se onde vc é, eu sou de Salvador, mas pelo que vi no site diversos estados tem e tb há a possibilidade de pedir o envio. Tenho um poucode medo pq da toxidade do ipilimumab, mas a verdade é que não aguento mais não ver efeito em nda. 21 de março de 2012 18:52. Deus está com vocês! Cartas par...
desafiandomelanoma.blogspot.com
Desafiando o Melanoma: Internação
http://desafiandomelanoma.blogspot.com/2012/04/internacao.html
Never, Never, Never Give Up" (Winston Churchill). Terça-feira, 10 de abril de 2012. Ana Cintia Cassab Heilborn. Compartilhar com o Pinterest. 11 de abril de 2012 07:15. Que Deus lhes abençõe e fortaleça. Abços. Ana Cintia Cassab Heilborn. 12 de abril de 2012 17:28. 11 de abril de 2012 14:39. Um beijo enorme neste coração lindo! E muita força e coragem. Ana Cintia Cassab Heilborn. 12 de abril de 2012 17:36. Obrigada pela força e pela torcida e espero seu contato. Bjs, Cintia. 13 de agosto de 2013 05:48.
desafiandomelanoma.blogspot.com
Desafiando o Melanoma: Aniversário
http://desafiandomelanoma.blogspot.com/2012/06/aniversario.html
Never, Never, Never Give Up" (Winston Churchill). Quinta-feira, 21 de junho de 2012. Eu sempre adorei fazer aniversário. Adorava a semana, o mês do meu aniversário. Passava dias atormentando o meu pai, pedindo presentes e mais presentes. Anotava na agenda dele, deixava bilhetinhos. Até o ano passado. Meu Deus, que falta você me faz! A morte deixa uma dor que não tem cura. Ana Cintia Cassab Heilborn. Compartilhar com o Pinterest. 25 de junho de 2012 08:07. 29 de junho de 2012 06:27. Blogs que eu sigo:.
TOTAL LINKS TO THIS WEBSITE
225
7th Annual Pharma Strategic Sourcing and Procurement Summit
STAY UPDATED FOR NEXT ANNUAL! 7th Annual Pharma Strategic Sourcing and Procurement Summit. STAY UPDATED FOR NEXT ANNUAL. STAY UPDATED FOR NEXT ANNUAL. STAY UPDATED FOR NEXT ANNUAL. SEE THE PAST SPEAKERS and CASE STUDIES. Senior Procurement Director – Technology, Travel, Meetings and Events, Payment Solutions, Fleet. Sr Director Global Procurement. Sr Manager, Global Strategic Sourcing. PAST CASE STUDIES INCLUDE. BMS Supply Chain Director. Packaging Supply on Demand Through Digital Supplier Integration.
PharmaStrategies
Was successfully added to your cart. Enhance your company's well-being. Going above and beyond to deliver. The pharmaceutical products you need,. When you need them. Our services allow you to focus on what really matters, innovation. From developing new therapies that treat, prevent and even eradicate disease, today’s pharmaceutical companies are focused on innovation and improving health and well being around the world. We aspire to assist our clients through:. Sourcing commercial drugs for clinical tri...
PharmaStrategies
PharmaStrategies, LLC offers a full range of Pharmacy Benefits Management consulting services. Our suite of products and services provide clear navigation through the complex and dynamic pharmacy benefits environment. EXPLORE our suite of services. Prescription medication discount cards for any type of member regardless of insurance status. Insightful and meaningful reports and data analysis that drive success. Expert vendor selection and management that provide confidence in a complex environment.
The Pharmaceutical Strategist
Seeing in Four Dimensions. With space-time compression, one can see into the future just by looking at spatial relations between events. Any one with access to satellite imagery watching the Ethiopians building the Renaissance Dam can pick up his smart phone and tweet pharaoh in Cairo:. 8220;Pharaoh, you are in for a very long drought”. 8220;How do you know? 8220;I can see it right now. Your future has just happened! The future is now, it is simply not equally distributed. Subscribe to: Posts (Atom).
pharmastrategy.net
Pharma Strategy Blog | Commentary on Pharma & Biotech Oncology / Hematology New Product Development
Commentary on Pharma and Biotech Oncology / Hematology New Product Development. Developing a predictive biomarker for PARP inhibition. Update on RAF resistance in metastatic melanoma. Red and Green Flags in cancer research and development. Will intermittent dosing transform TKI therapy in cancer research? Making a difference in NHL and CLL: an interview with Dr Carol Gallagher. Medivation announce interim results of PREVAIL in pre-chemotherapy CRPC. Can Merck make an impact in pancreatic cancer? Dr Carol...
Pharma Strategy and Competitive Intelligence | Data Driven Pharma Biotech Business Intelligence
Pharma Strategy and Competitive Intelligence. Data Driven Pharma Biotech Business Intelligence. Useful sources of competitive intelligence. For those interested in business and competitive intelligence, take a look at the Society of Competitive Intelligence Professionals (SCIP). It’s open to all industries, not just pharmaceuticals and biotechnology. There is also a useful portal on Ning, many of whom are SCIP members. Increasing importance of competitive intelligence in bear markets. Johnson and Johnson...
風俗にいってそこでしか味わえないサービスを受けることができる
Pharma Strategy Reports
Insightful reports on cancer drug development. Coming soon - mini reports on cancer pathways and novel targets from @MaverickNY. Sign up for our email list if you want to be the first to know when these are available! FDA Breakthrough Designation Report. Want to know whether the FDA Breakthrough Therapy designation is hype over hope or will have a real impact on cancer drug development, read our latest mini report. Coming soon! ASCO 2014 Preview Video. Welcome to Pharma Strategy Reports.
pharmastreet.com - This website is for sale! - pharmastreet Resources and Information.
The owner of pharmastreet.com. Is offering it for sale for an asking price of 5000 USD! The owner of pharmastreet.com. Is offering it for sale for an asking price of 5000 USD! This webpage was generated by the domain owner using Sedo Domain Parking. Disclaimer: Sedo maintains no relationship with third party advertisers. Reference to any specific service or trade mark is not controlled by Sedo nor does it constitute or imply its association, endorsement or recommendation.
SOCIAL ENGAGEMENT